Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Observer-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum, in Healthy Women of Child-Bearing Age

NCT01704365 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT01704365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01704365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Observer-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum, in Healthy Women of Child-Bearing Age
Lead sponsor
Novavax
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
May 31, 2013
Enrollment
330 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)